Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
Based on MGA’s independent analysis, the Teva Global Economic Impact Report estimates Teva’s economic impact in 19 of the 60 countries in which Teva operates.
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.
This paper estimates the savings opportunity from biosimilars in the medical benefit of a large employer-sponsored health plan, using real-world claims data. This analysis illustrates the savings potential of biosimilars in the commercial market and highlights the important role of employer-sponsored plans in promoting biosimilar utilization.
“Matrix Global Advisors pointed out where the focus on fighting opioids needs to be. Approximately 36 percent of people that are misusing painkillers get their drugs from doctors.”
This week, two healthcare publications referenced MGA’s recent report concerning the HHS OIG proposed rule to restrict drug manufacturer rebates to pharmacy benefit managers (PBMs).
This MGA analysis details concerns with a proposed rule from the Health and Human Services Office of Inspector General that would restrict drug manufacturer rebates to pharmacy benefit managers in Medicare Part D and Medicaid Managed Care Organizations. Not only does the propose rule lack evidence, but it is poorly targeted to achieve its stated goals. I
In a new paper sponsored by Women In Government, MGA examines why a proposed tax on prescription opioids would be ineffective and details the unintended consequences of this policy.
In a new paper, MGA discusses why the biosimilars market in the United States is not more developed and what steps can be taken to boost competition for biologic drugs. The paper identifies barriers to biosimilars by four categories, related to reference product manufacturers, biosimilar manufacturers, policy, and stakeholder education and awareness. Among the strategies to overcoming barriers are more physician and patient education, competitive biosimilar pricing, action by employer-sponsored health plans and private payors to encourage biosimilar utilization, and continued FDA efforts to support the budding market.
A new study from MGA examines the practice by brand drug manufacturers of using Risk Evaluation and Mitigation Strategies (REMS) and other forms of restricted access to keep generic manufacturers from obtaining samples needed to develop generic drugs. MGA estimates that this misuse blocks $13.4 billion in generic savings annually, an estimate that has grown nearly 250 percent since MGA’s 2014 analysis of this issue.